Canaccord Genuity analyst Arlinda Lee raised her price target for Nektar Therapeutics to $94 after the company reported Q4 results. Notable, Nektar provided a second update to Phase 1 Pivot-2 dose-escalation results indicating ongoing and further tumor shrinkage with improved and continuing response, Lee tells investors in a research note. Further, the company reported 60% response rate in 20 patients with PDL1-negative tumors at baseline, the analyst adds. She believes the update "further solidifies the central positioning" for wholly-owned drug candidate NKTR-214 in combination with anti-PD1. The analyst keeps a Buy rating on Nektar.

Biolojic Design announced that Nektar exercised its license option to develop a program resulting from the companies' research collaboration initiated in 2021. The research collaboration was established to design and test agonistic antibodies targeting tumor necrosis factor receptor type II, a novel, biologically-validated disease target implicated in a wide range of autoimmune diseases that has been difficult to drug with conventional medicines. The antibody program selected for development is designed to modulate the TNFR2 pathway in order to agonize - or activate - T regulatory cells and other anti-inflammatory cell populations, making this a promising approach to stimulating the immune system in ulcerative colitis, multiple sclerosis, vitiligo, and other autoimmune disease states. Under the 2021 research agreement, Nektar has tested antibodies computationally designed by Biolojic Design to precisely agonize the TNFR2 receptor. Following successful preclinical in vitro and in vivo studies, Nektar decided to exercise the license option and has been advancing the program through IND enabling studies since late December, 2023. If the NKTR-0165 candidate proceeds through clinical development, Biolojic Design is entitled to development milestones and sales royalties.